The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Expert Testimony - Roche; SERVIER
A self-assessment survey to identify the risk of screen failure in phase I clinical trials (SCITEP score).
 
Kaissa Ouali
Consulting or Advisory Role - Sotio
Travel, Accommodations, Expenses - Amgen; Sotio
 
Imene Deneche
No Relationships to Disclose
 
Lauren Seknazi
No Relationships to Disclose
 
Rastilav Bahleda
No Relationships to Disclose
 
Aurore Vozy
No Relationships to Disclose
 
Perrine Vuagnat
No Relationships to Disclose
 
Francois-Xavier Danlos
No Relationships to Disclose
 
Vincent Goldschmidt
Travel, Accommodations, Expenses - MSD
Other Relationship - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer HealthCare Pharmacuticals (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol Myers Squibb Foundation (Inst); CASI Pharmaceuticals (Inst); Cato Research (Inst); CellCentric (Inst); Cellgen (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Eisai (Inst); EverImmune (Inst); Exelixis (Inst); Faron Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); ImCheck therapeutics (Inst); Incyte (Inst); Innate Pharma (Inst); Iris International (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Janssen Oncology (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Kyowa Kirin International (Inst); La Roche-Posay (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Menarini (Inst); SERVIER (Inst)
 
Arnaud Bayle
Consulting or Advisory Role - Sanofi
 
Patricia Martin Romano
No Relationships to Disclose
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Spectrum Pharmaceuticals (Inst); Taiho Oncology
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Jean-Marie Michot
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Astex Pharmaceuticals (Inst)
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Deka Biosciences; HotSpot Therapeutics; Marengo Therapeutics; Shattuck Labs
Consulting or Advisory Role - Adagene; AstraZeneca; BiolineRx; Centessa Pharmaceuticals; Clover Biopharmaceuticals; Deka Biosciences; Depth Charge Therapeutics; EISAI; Grey Wolf Therapeutics; Gritstone Bio; Guidepoint Global; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MSD; Neogene Therapeutics; OSE Immunotherapeutics; Pegaone; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Shattuck Labs; Sotio; Third Rock Ventures
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - Sotio
Other Relationship - Elsevier
 
Sophie Postel-Vinay
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Tesaro (Inst); Roche/imCORE (Inst)
 
Anas Gazzah
No Relationships to Disclose
 
Cristina Smolenschi
No Relationships to Disclose
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Santiago Ponce Aix
No Relationships to Disclose
 
Stephane Champiat
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; BioNTech SE; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom; Nanobiotix; NextCure; Oncovita; Pierre Fabre; Seagen; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen; Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); CellCentric (Inst); Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); CureVac (Inst); Cytovation; Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai/H3 Biomedicine; Exelixis (Inst); Faron Pharmaceuticals (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); ImCheck therapeutics; Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners; Molecular Partners (Inst); MSD; Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); OSE Immunotherapeutics; Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre; Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Relay Therapeutics (Inst); RigonTEC (Inst); Roche (Inst); Roche (Inst); Sanofi; Sanofi (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio; Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Transgene; Transgene (Inst); Turning Point Therapeutics (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAguix (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
 
Capucine Baldini
Consulting or Advisory Role - Bicycle Therapeutics; Janssen Oncology; Rising Tide Foundation
Research Funding - Foundation BMS (Inst)
Expert Testimony - Abbvie; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Roche/Genentech